![John Thornback](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Thornback
Vorsitzender bei Centre For Probe Development & Commercialization
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
John Valliant | M | 54 |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | 16 Jahre |
Damian Lamb | M | 52 |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | - |
Bruno Paquin | M | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | - |
Jean-Claude Provost | M | 60 |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | - |
Lana Janes | M | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | 3 Jahre |
Sheila Singh | M | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | 3 Jahre |
Bettina Hamelin | M | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | 3 Jahre |
Peter Pattison | M | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | 3 Jahre |
Karen Gulenchyn | F | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | - |
Annick Van den Abbeele | M | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | - |
Gay Yuyitung | M | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | - |
Christopher Kelly | M | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | - |
Constantinos Economou | M | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | - |
Anton Knezovic | M | - |
Centre For Probe Development & Commercialization
![]() Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jehad Abdel Hamid El-Nakla | M | 56 |
Loughborough University
| - |
Dipesh Patel | M | - |
Loughborough University
| 8 Jahre |
Abdulmohsen Abdullah Al-Kharafi | M | - |
Loughborough University
| 3 Jahre |
Paul Gregory Reed | M | 56 |
Loughborough University
| 4 Jahre |
Claire Combes | F | - |
Loughborough University
| 4 Jahre |
Jonathan Edward Morris | M | 61 |
Loughborough University
| 4 Jahre |
Gavin Cooper | M | - |
Loughborough University
| 4 Jahre |
Andrew Hinkly | M | 59 |
Loughborough University
| 4 Jahre |
Andrew Dillon | M | - |
Loughborough University
| 3 Jahre |
Tim Mills | M | - |
Loughborough University
| 4 Jahre |
Martin E. Siegrist | M | - |
Loughborough University
| 4 Jahre |
Mohamad Razali bin Othman | M | 72 |
Loughborough University
| 1 Jahre |
Kim Meng Koh | M | - |
Loughborough University
| 4 Jahre |
André Hergert | M | - |
Loughborough University
| 4 Jahre |
Chi Man Yau | M | 61 |
Loughborough University
| 4 Jahre |
Tobias Martin Ellwood | M | 57 |
Loughborough University
| 5 Jahre |
Steve Varley | M | - |
Loughborough University
| 4 Jahre |
Roger William Brown | M | 62 |
Loughborough University
| 4 Jahre |
Roderick Mason | M | 60 |
Loughborough University
| 1 Jahre |
Jit Peng Cheah | M | 59 |
Loughborough University
| 4 Jahre |
Andrew Knox | M | 58 |
Loughborough University
| 3 Jahre |
Andrew Ripper | M | - |
Loughborough University
| 4 Jahre |
Pan Chang | M | 60 |
Loughborough University
| 3 Jahre |
Ray Smith | M | - |
Loughborough University
| 4 Jahre |
Richard Brice | M | - |
Loughborough University
| 4 Jahre |
Stanley Elder | M | - |
Loughborough University
| 4 Jahre |
Andrew John Crossley | M | 61 |
Loughborough University
| 4 Jahre |
Tim Dyson | M | 64 |
Loughborough University
| 4 Jahre |
Teng Cheong Khoo | M | - |
Loughborough University
| 4 Jahre |
Brian Tear | M | - |
Loughborough University
| 4 Jahre |
Steven Derek Clarke | M | 56 |
Loughborough University
| 4 Jahre |
Christopher Michael David Ross-Roberts | M | 60 |
Loughborough University
| 4 Jahre |
Simon Dominic Stevens | M | 58 |
Loughborough University
| 2 Jahre |
Ramasamy Sinnakaruppan | M | 66 |
Loughborough University
| 1 Jahre |
Nigel J. Whitehead | M | 63 |
Loughborough University
| 4 Jahre |
Stuart James Miller | M | 57 |
Loughborough University
| 4 Jahre |
Julian Simon Johns Swain | M | 58 |
Loughborough University
| 1 Jahre |
Matthew Foulston | M | 60 |
Loughborough University
| 3 Jahre |
Steven Townend | M | 54 |
Loughborough University
| 5 Jahre |
John Paul Goodwin | M | 60 |
Loughborough University
| 4 Jahre |
Antony Cooper | M | 62 |
Loughborough University
| 4 Jahre |
Lian Guan Pek | M | 58 |
Loughborough University
| 4 Jahre |
Tony Cooper | M | - |
Loughborough University
| 4 Jahre |
Fawaz bin Abdulaziz Fahad Al-Hokair | M | 59 |
Loughborough University
| 4 Jahre |
Jonathan Mark Huntley | M | - |
Loughborough University
| 3 Jahre |
Hamzah bin Hasan | M | 73 |
Loughborough University
| 1 Jahre |
Chian Tat Ah Teck | M | 62 |
Loughborough University
| 1 Jahre |
Jonathan Sinclair | M | 62 |
Loughborough University
| 4 Jahre |
Graham Michael Rhodes | M | 62 |
Loughborough University
| 4 Jahre |
Ian Woods | M | - |
Loughborough University
| 4 Jahre |
Saini bin Ali | M | 63 |
Loughborough University
| 4 Jahre |
Mizan Nicholas Denney | M | 63 |
Loughborough University
| 4 Jahre |
Adrian Parkinson | M | - |
Loughborough University
| 4 Jahre |
Thomas J. Maddison | M | 60 |
Loughborough University
| 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigtes Königreich | 54 | 79,41% |
Kanada | 14 | 20,59% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- John Thornback
- Persönliches Netzwerk